DDO1002, an NRF2–KEAP1 inhibitor, improves hematopoietic stem cell aging and stress response
Yuwen Li, Aiwei Wu, Xinrong Jin, Haiping Shen, Chenyan Zhao, Xiao Yi, Hui Nie, Mingwei Wang, Shouchun Yin, Hongna Zuo, Zhenyu Ju, Zhenyu Jiang, Hu Wang · 2024
Read DDO1002, an NRF2–KEAP1 inhibitor, improves hematopoietic stem cell aging and stress response by Yuwen Li, Aiwei Wu, Xinrong Jin, Haiping Shen, Chenyan Zhao, Xiao Yi, Hui Nie, Mingwei Wang, Shouchun Yin, Hongna Zuo, Zhenyu Ju, Zhenyu Jiang, Hu Wang (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11748272.txt.
Description
Yuwen Li and twelve co-authors test a drug in 2024 that frees the body's antioxidant master switch to rescue aging blood stem cells. As these stem cells age, oxygen byproducts scar their DNA and dull their output. The drug blocks the switch's keeper protein, letting protective genes turn on.
In mice, the treatment lowered the harmful oxygen species, eased cell aging, and cut DNA damage after whole-body radiation. Stem cells from treated old mice rebuilt blood better in transplant contests and renewed themselves more ably. Single-cell reads showed calmer inflammation inside the cells. The authors pitch the compound for age-related blood decline.
Catalog record
| CREATOR | Yuwen Li, Aiwei Wu, Xinrong Jin, Haiping Shen, Chenyan Zhao, Xiao Yi, Hui Nie, Mingwei Wang, Shouchun Yin, Hongna Zuo, Zhenyu Ju, Zhenyu Jiang, Hu Wang |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 53 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |